NEW YORK (GenomeWeb) – Genection, a subsidiary of Invivoscribe Technologies, has launched a next-generation sequencing-based panel for acute myeloid leukemia — the first of several NGS-based cancer tests that it intends to submit to the US Food and Drug Administration for 510(k) clearance.

San Diego-based Genection, which was launched in 2012, is combining its sequencing analysis capabilities with its parent company's expertise in hematological diseases, and specifically AML, to launch the panel, dubbed MyAML.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.